Steba Biotech S.A.   Report issue

For profit Phase 2 Phase 4
Founded: Luxembourg (1996)

Organization Overview

First Clinical Trial
2004
NCT00308919
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Steba Biotech S.A. | STEBA France | STEBA LABORATORIES LTD.

Active Ingredients

Drugs in Phase 4 Trials (1)

padeliporfin (Tookad) (9 trials)

Drugs in Phase 2 Trials (3)

stakel (1 trial)

tenatoprazole (2 trials)

wst11 (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Cholangiocarcinoma (Phase 2)

Choroidal Neovascularization (Phase 2)

Deglutition Disorders (Phase 1)

Duodenal Ulcer (Phase 1)

Enuresis (Phase 4)

Erectile Dysfunction (Phase 4)

Esophagitis (Phase 2)

Esophagitis, Peptic (Phase 2)

Gastroesophageal Reflux (Phase 1)

Kidney Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Macular Degeneration (Phase 2)

Neovascularization, Pathologic (Phase 2)

Prostatic Neoplasms (Phase 4)

Stomach Ulcer (Phase 1)

Ulcer (Phase 1)

Urinary Incontinence (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 4